Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 118

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 118
---
 audit committee report required by the SEC rules (which is included on page 11 of this proxy statement).                                |

| 82 |

The Audit Committee charter is available on the Investors page of our website at www.indaptusrx.com. The members of the Audit Committee are Mr. Hayes, Ms. Karah, and Dr. Martell. Mr. Hayes serves as the Chairperson of the committee. Our Board has affirmatively determined that each of Mr. Hayes, Ms. Karah, and Dr. Martell is independent for purposes of serving on an audit committee under Rule 10A-3 promulgated under the Exchange Act and the Nasdaq Rules, including those related to Audit Committee membership.

The members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules. In addition, our Board of Directors has determined that Mr. Hayes qualifies as an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of Regulation S-K, and under the similar Nasdaq Rules requirement that the Audit Committee have a financially sophisticated member.

Compensation Committee

Our Compensation Committee is responsible for assisting the Board in the discharge of its oversight responsibilities relating to the evaluation of our executive officers (including the Chief Executive Officer), determining the compensation of our executive officers, and overseeing the management of risks associated therewith. In fulfilling its purpose, our Compensation Committee has the following principal duties:

| ● | reviewing                                                                                                                            
 and approving, or recommending for approval by the Board, our overall compensation strategy and policies, including evaluating risks 
 associated with our compensation policies and practices;                                                                             |
| ● | reviewing                                                                                                                            
 and approving, or recommending for approval by the Board, the compensation of our CEO and our other executive officers;              |
| ● | overseeing                                                                                                                           
 and administering our cash and equity incentive plans;                                                                               |
| ● | reviewing                                                                                                                            
 and making recommendations to the Board of Directors with respect to non-employee director compensation;                             |
| ● | reviewing                                                                                                                            
 and discussing annually with management our “Compensation Discussion and Analysis,” to the extent required; and                      |
| ● | preparing                                                                                                                            
 the annual compensation committee report, to the extent required by SEC rules.                                                       |

The Compensation Committee generally considers the Chief Executive Officer’s recommendations when making decisions regarding the compensation of executive officers (other than the Chief Executive Officer). Pursuant to the Compensation Committee’s charter, which is available on the Investors page of our website at www.indaptusrx.com, the